Avacta completes Coris sale in final diagnostics exit: Is its precision oncology pivot ready for prime time?

The transformation of Avacta Group plc (AIM: AVCT) into a pure-play oncology company is now complete. The UK-based life sciences firm confirmed the completion of its sale of Coris Bioconcept SRL to 3B BlackBio Dx Ltd, in a move that further tightens its operational and strategic focus around the pre|CISION® tumor-activated drug delivery platform. With the last of its diagnostics business off the books, Avacta is officially repositioning itself as a specialist in targeted cancer therapeutics—but investors may now start asking: Can the science deliver in time?

The sale, which closed on August 29, 2025, follows a July announcement that the deal would proceed for £2.15 million in upfront cash, inclusive of net cash and working capital adjustments. The agreement also includes a performance-based earn-out of up to £0.615 million, depending on Coris’ future business trajectory. The buyer, 3B BlackBio Dx Ltd, gains full control of the Belgium-based diagnostics firm, which had been part of Avacta’s broader diagnostics division.

Why did Avacta exit diagnostics—and how does this reshape its capital allocation strategy?

The divestment of Coris is the culmination of a broader divestiture campaign that began with the March 2025 sale of Launch Diagnostics, another key diagnostics unit previously held by Avacta. With both Launch and Coris now sold, Avacta has effectively unwound all operations outside its therapeutics portfolio.

According to Chief Executive Officer Dr. Christina Coughlin, the disposal represents a “pivotal final step” in Avacta’s transition to a singular focus on oncology. The proceeds from the Coris sale will be redirected into the advancement of Avacta’s proprietary pre|CISION® drug conjugate pipeline, enabling the firm to extend its cash runway and commit more fully to its clinical programs.

Operationally, the disposal eliminates the complexity and capital burden of managing a diagnostics business, while financially, it aligns Avacta’s balance sheet and investor story with the higher-reward (albeit higher-risk) domain of precision oncology.

What makes the pre|CISION® platform central to Avacta’s therapeutic ambitions?

Avacta’s pre|CISION® platform is a drug conjugate delivery system designed to improve the safety and effectiveness of cancer treatments by ensuring that cytotoxic payloads are released only within the tumor microenvironment. The core innovation lies in a proprietary peptide linker, which is cleaved exclusively by fibroblast activation protein (FAP)—a tumor-specific protease upregulated in most solid tumors but absent or minimally present in healthy tissue.

This specificity enables Avacta to deliver highly potent payloads, including those traditionally associated with high systemic toxicity, in a way that minimizes collateral damage to healthy cells. The company is developing both peptide drug conjugates (PDCs) and Affimer® drug conjugates (AffDCs), each leveraging this FAP-activated release mechanism.

By concentrating drug activation at the tumor site, the platform offers a differentiated approach versus traditional antibody-drug conjugates (ADCs). While ADCs have proven effective in some settings, their systemic toxicity profiles often limit dosing, especially in solid tumors. Avacta’s platform promises to mitigate these limitations—at least in theory.

The company’s long-term bet is that tumor-activated payload release could unlock a new class of cancer drugs with optimized efficacy, tolerability, and dosing flexibility.

What did the Coris business contribute—and how does its disposal impact Avacta’s financials?

Coris Bioconcept SRL reported unaudited revenues of €5.22 million for the year ended 31 December 2024, with most of its business driven by non-COVID diagnostic products. Despite a stable revenue base, Coris posted negative EBITDA of €0.215 million and had net assets of €4.14 million at year-end.

The sale of Coris allows Avacta to streamline operations and focus on its higher-margin therapeutic business. However, the disposal also triggered a non-cash impairment charge of £6.8 million in FY24, which was pre-announced and factored into the Group’s reported financials.

Crucially, the cash proceeds from the transaction are expected to extend Avacta’s funding runway into Q1 2026, giving the company additional breathing room to progress its lead assets through early-phase trials and deliver the kind of data investors will demand before committing further capital.

How are markets responding—and what is the near-term stock outlook for AVCT?

At the close of trading on September 2, 2025, Avacta shares finished at GBX 60.80, down 1.14% (−0.70p) for the day. The intraday high touched GBX 62.00, while the low settled at GBX 60.80—a narrow range reflecting low volatility. The bid/offer spread of GBX 59.00 / 61.00 remains stable, and trading volume appears consistent with recent historical averages.

Investor sentiment appears cautiously neutral. The modest dip likely reflects a “sell the news” dynamic rather than fundamental concerns about the Coris deal, which had been widely expected following the July announcement. From a technical standpoint, the GBX 60.00 level appears to be acting as psychological support, while upside momentum remains contingent on clinical updates.

With Avacta now repositioned as a high-risk, high-reward clinical-stage biotech, the next phase of investor attention will likely be dominated by data readouts, dosing updates, and progress toward IND filings or Phase I/II milestones.

What does this mean for institutional sentiment—and is the pivot credible?

Institutions tracking Avacta over the past year have been seeking clarity on its long-term strategy. The two-part diagnostics exit—first Launch Diagnostics, then Coris—has provided that clarity. The shift to a singular, oncology-focused narrative may help Avacta better align with specialist biotech investors, many of whom prefer focused, platform-driven drug developers with clean asset portfolios.

However, the move also raises expectations. By shedding its revenue-generating diagnostics businesses, Avacta has signaled that it believes the therapeutic upside outweighs the near-term dilution risk associated with fundraising for clinical trials. This may increase pressure from institutional backers to deliver timely and high-quality clinical data—especially ahead of any further capital raise expected post-Q1 2026.

What are the biggest risks—and where does the story go from here?

With diagnostics now behind it, Avacta is essentially betting the farm on its pre|CISION® platform. That makes execution risk extremely high. As of now, the company remains clinical-stage, and no product has reached Phase III, let alone regulatory filing or commercialization. Delays in data, safety concerns, or regulatory pushback could have an outsized impact on market cap and investor confidence.

In contrast, meaningful early-phase data—particularly around safety, tumor selectivity, and tolerability—could validate the company’s approach and set the stage for partnerships or licensing opportunities. Some analysts speculate that the Affimer® component of the platform could be of particular interest to larger oncology players seeking alternatives to traditional ADCs.

One area to watch is how Avacta communicates its development timelines over the next two quarters. The company will need to balance investor appetite for progress updates with the reality of early-stage drug development, which is often slow, iterative, and data-dependent.

With diagnostics in the rearview mirror, Avacta’s pure-play biotech bet begins

The sale of Coris Bioconcept SRL represents more than just a portfolio cleanup—it’s a line in the sand. Avacta is now, unequivocally, a clinical-stage biotech company focused on oncology therapeutics, with all the risk and upside that designation entails.

The market’s verdict on this strategy will not come from headlines but from molecules—from data that proves whether Avacta’s tumor-activated conjugates can truly outperform existing cancer therapies. With a runway into Q1 2026 and a streamlined balance sheet, the clock is ticking. For now, investors are watching, waiting—and betting on science.